Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Erstveröffentlichung
2021Authors
Fasching, P. A.
Link, T.
Hauke, J.
Seither, F.
Jackisch, C.
Wissenschaftlicher Artikel
Published in
Annals of Oncology ; 32 (2021), 1. - S. 49-57. - ISSN 0923-7534. - eISSN 1569-8041
Link to publication
https://dx.doi.org/10.1016/j.annonc.2020.10.471Institutions
UKU. Klinik für Frauenheilkunde und GeburtshilfeSubject headings
[Free subject headings]: PARP inhibitor | HER2-negative breast cancer | HRD | neoadjuvant therapy | olaparib | carboplatinum | PATHOLOGICAL COMPLETE RESPONSE | CHEMOTHERAPY | CARBOPLATIN | GEPARSIXTO | SURVIVAL | MUTATION[DDC subject group]: DDC 610 / Medicine & health